1. Home
  2. SRBK vs INMB Comparison

SRBK vs INMB Comparison

Compare SRBK & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRBK
  • INMB
  • Stock Information
  • Founded
  • SRBK 1887
  • INMB 2015
  • Country
  • SRBK United States
  • INMB United States
  • Employees
  • SRBK N/A
  • INMB N/A
  • Industry
  • SRBK
  • INMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • SRBK
  • INMB Health Care
  • Exchange
  • SRBK Nasdaq
  • INMB Nasdaq
  • Market Cap
  • SRBK 118.4M
  • INMB 49.2M
  • IPO Year
  • SRBK N/A
  • INMB 2019
  • Fundamental
  • Price
  • SRBK $15.30
  • INMB $1.69
  • Analyst Decision
  • SRBK
  • INMB Hold
  • Analyst Count
  • SRBK 0
  • INMB 3
  • Target Price
  • SRBK N/A
  • INMB $4.30
  • AVG Volume (30 Days)
  • SRBK 23.3K
  • INMB 380.0K
  • Earning Date
  • SRBK 10-30-2025
  • INMB 10-30-2025
  • Dividend Yield
  • SRBK 1.31%
  • INMB N/A
  • EPS Growth
  • SRBK 374.69
  • INMB N/A
  • EPS
  • SRBK 0.54
  • INMB N/A
  • Revenue
  • SRBK $31,130,000.00
  • INMB $50,000.00
  • Revenue This Year
  • SRBK N/A
  • INMB $191.43
  • Revenue Next Year
  • SRBK N/A
  • INMB $12,299.51
  • P/E Ratio
  • SRBK $28.21
  • INMB N/A
  • Revenue Growth
  • SRBK 0.85
  • INMB 19.05
  • 52 Week Low
  • SRBK $11.19
  • INMB $1.38
  • 52 Week High
  • SRBK $15.46
  • INMB $11.64
  • Technical
  • Relative Strength Index (RSI)
  • SRBK 65.84
  • INMB 52.07
  • Support Level
  • SRBK $14.91
  • INMB $1.46
  • Resistance Level
  • SRBK $15.41
  • INMB $1.62
  • Average True Range (ATR)
  • SRBK 0.21
  • INMB 0.10
  • MACD
  • SRBK 0.02
  • INMB 0.02
  • Stochastic Oscillator
  • SRBK 91.36
  • INMB 86.70

About SRBK SR Bancorp Inc. Common stock

SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.

About INMB INmune Bio Inc. Common stock

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.

Share on Social Networks: